Genmab — September 2016
-
Den steg pænt efter Børsen havde artiklen på.
-
Nordea havde den på i morges.
-
Bulder havde kilden på i går aftes. http://www.onclive.com/web-exclusives/daratumumab-produces-dramatic-responses-in-relapsed-light-chain-amyloidosis
-
-
Det lyder næsten for godt til at være sandt:"Response, including complete response, occurred as early as 1 month (or sooner) after the start of treatment. As an example of the activity observed in the study, Kaufman described a patient who had received 6 prior lines of therapy, including autologous stem-cell transplantation, and achieved a complete response within the first month after starting daratumumab infusions".
-
18 patienter...16 får respons. Bingo: "
In addition to the 6 patients who achieved complete responses with daratumumab, 3 patients had very good partial responses, and 7 had partial responses. Only 2 patients did not achieve an objective response to treatment with daratumumab, Kaufman reported". -
Det er suveræne tal, men selvfølgelig bliver der forsket i, hvorfor de sidste to ikke fik respons.
-
Kan være Kaufman's studie kan sætte skub i de to ISS-studier der er registreret på CT https://www.clinicaltrials.gov/ct2/results?term=daratumumab+and+amyloidosis&Search=Search
-
Ok.
-
NBIge steg 3% i går. Er lige nu 0,97% nede.
-
Det ses på kursen at USA er i rødt og NBI i -1,97% nu.
-
Enig OHW..RSI er en god indikator.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind